Method for non-evasively determining an endothelial function and a device for carrying out said method

Information

  • Patent Grant
  • 10238306
  • Patent Number
    10,238,306
  • Date Filed
    Monday, April 3, 2006
    18 years ago
  • Date Issued
    Tuesday, March 26, 2019
    5 years ago
Abstract
The invention relates to medicine. The inventive method for non-evasively determining an endothelial function consists in reducing a transmural pressure in a limb, recording the amplitude of plethysmographic signals at different pressures, determining the pressure of a maximum plethysmographic signal amplitude, reducing the pressure to a value corresponding to the specified percentage of the maximum amplitude, carrying out an occlusion sample in the course of which a pressure higher by at least 50 mm Hg than the systolic pressure of a tested patient is produced in a cuff arranged proximally to the located limb area, wherein the occlusion is carried out during at least 5 minutes. The inventive device for carrying out said method comprises a sensory unit, a pressure producing unit, an electronic unit constructed in such a way that it makes it possible to measure the cuff pressure corresponding to the maximum plethysmographic signal amplitude and a unit for controlling the pressure producing unit in such a way that the cuff pressure corresponding to the amplitude of a plethysmographic signal, which represents a specified percentage of the maximum amplitude, is attained. The sensory unit is connected to the electronic unit to the output of which the pressure producing unit is connected.
Description
BACKGROUND OF THE INVENTION
Area of Application

The invention applies to medicine, particularly to functional diagnostics, and allows early detection of cardiovascular diseases as well as the monitoring of the effectiveness of treatment received by the patient. The invention assesses the state of endothelial function and, based on this assessment, addresses the need of early diagnosis of cardiovascular disease. This invention can be used for widespread testing of the population.


Prior Art

As of late, the need for early cardiovascular disease detection has become more and more relevant. For this end a wide spectrum of means and methods described in patent and scientific literature is used. For example, the U.S. Pat. No. 5,343,867 describes a method and apparatus for early diagnosis of atherosclerosis using impedance plethysmography to detect an irregular pulse wave in the arteries of the lower extremities. It is shown that blood flow parameters depend on the outside pressure applied to the artery under investigation. The maximum amplitude of the plethysmogram is in large determined by the size of the transmural pressure, which is defined as the difference between internal arterial pressure and the pressure applied externally by the cuff. Maximum amplitude is reached when the transmural pressure drops to zero.


From the perspective of the structure and physiology of blood vessels, this can be imagined to occur in the following manner: Pressure from the cuff transfers to the exterior of the artery and counterbalances the pressure of the interior of the artery wall. With this, the compliance of the arterial wall increases dramatically and the passing pulse wave stretches the artery to a large diameter, i.e. the increase of the arterial diameter at the same pulse pressure becomes significant. This phenomenon can be observed on an oscillometric curve, recorded during the taking of arterial pressure. The peak of the oscillometric curve corresponds to the moment when the pressure inside the cuff equals the mean arterial pressure.


U.S. Pat. No. 6,322,515 describes a method and apparatus for determining a set of cardiovascular parameters which are used for the evaluation of the state of endothelial function. Photodiodes and photoreceptors are used as pulse wave sensors, and an analysis of photo-plethysmographic waveforms is made. The measurements for these waveforms are taken at the observed artery before and after the test with reactive hyperemia. During the recording of these waveforms, the cuff, where the pressure is maintained at 70 mmHg, is placed on the digit, over the optical sensor.


U.S. Pat. No. 6,939,304 reveals a method and apparatus for non-invasive assessment of endothelial function using the photoplethysmography (PPG) sensor.


U.S. Pat. No. 6,908,436 reveals a method for the assessment of endothelial function by measuring the spreading of the pulse wave. For this a two-channel plethysmograph is used, sensors are mounted on one of the phalanges of the finger, and an occlusion is created with the help of the cuff placed on the shoulder. Changes in the state of the arterial wall are assessed based on the duration of delay in the spreading of the pulse wave. If the duration of the delay is 20 ms or longer, the delay is considered to confirm normal endothelial function. The duration of the delay is established by comparing it with the PPG waveform which is measured on the arm not influenced by the occlusion test. However, this method falls short when it comes to determining the delay of displacement in the area of the minimum directly before systolic growth, i.e. in the area which is to a significant extent variable.


The most analogous method and apparatus to the one described below is the method and apparatus for non-invasive evaluation of the physical state of the patient described in patent #2,220,653 of the Russian Federation. The method consists of the following: First a control of the peripheral arterial tone is established by distributing the pulse of the cuff across several sensors and raising the pressure in the cuff to 75 mmHg. Then arterial pressure is measured by raising the pressure in the cuff above the systolic pressure and keeping it there for five minutes. Pulse wave measurements are further taken on both arms by the PPG method. Finally the PPG waveform is analyzed with regard to its amplitude by comparing its values before and after the occlusion and determining the increase of the measured output. This apparatus includes a sensor for measuring pressure with the cuff, a heating element for heating the surface of the observed region of the body, and a processor for processing the measured output.


However, this method and this apparatus are not able to provide reliable results due to the low precision of measurements and their dependency on the fluctuating blood pressure of the patient.


BRIEF SUMMARY OF THE INVENTION

The endothelial dysfunction occurs in the presence of various risk factors for cardiovascular disease (CVD), such as high cholesterol levels, arterial hypertension, smoking, age and others. It is established that endothelial cells is the organ-target for the pathogenic realization of factors contributing to the risk of CVD development. The assessment of endothelial function acts as the “barometer” which allows early diagnosis of CVD. Such a diagnostic approach will allow a departure from the current approach were a set of biochemical tests must be administered to the patient (determining the levels of cholesterol, high and low-density lipoproteins, and others) in order to detect the presence of risk factors. During the early stages of CVD it is economically sound to screen the population using internal indicators for the risk of disease development. One such indicator is the state of endothelial function. The assessment of this state is also extremely relevant for the quality assessment of received therapies.


The goal of this invention is to create a physiologically-based non-invasive method and apparatus for reliably determining the state of endothelial function in the patient. This method and apparatus will offer an individualized approach based on the particular conditions of the patient. The method and apparatus will be based on a system of conversion, amplification, and recording of the PPG output during the onset of the optimal magnitude of the established pressure or pressure locally applied to the observed artery before and after the occlusion test.


The technical result, which is achieved with the use of the aforementioned device and apparatus, is centered on reliable assessment of endothelial function regardless of the arterial pressure of the patient.


In terms of method, the technical result is achieved through a series of steps. First, the transmural pressure in the artery is lowered. Then the amplitude of plethysmographic output is measured at various pressures. Once the pressure at which the amplitude of the PG signal is maximal is established, the pressure is lowered to a predetermined percentage of the maximal amplitude. Finally, an occlusion test is performed for at least five minutes. During this test a pressure is created in the cuff which is placed on the observed region of the extremity. This pressure must exceed the measured systolic pressure by at least 50 mmHg.


The technical result is amplified because the transmural pressure is lowered when the pressure-generating cuff is placed on a particular region of the extremity.


The pressure on the extremity is raised gradually every five to ten seconds by increments of 5 mmHg. At each step the amplitude of the PG output is measured and recorded.


A mechanical pressure is locally applied to the extremity in order to lower the transmural pressure in the observed artery.


In order to lower the transmural pressure in the observed artery, the hydrostatic pressure is lessened by raising the extremity a specified height above the level of the heart.


The intensity of the transmural pressure is established when the amplitude of the PG output is 50% that of the maximal PG output. This pressure is created in the cuff which is placed in close proximity to the observed artery. Then super-systolic pressure is created and the plethysmographic output is recorded.


After at least five minutes of exposure to the occlusion cuff placed near the observed artery, the pressure in the cuff is lowered to zero. The changes in the PG output reading are recorded simultaneously by the reference channel and the monitoring channel for at least five minutes.


After the occlusion test, the recorded plethysmographic signal is analyzed using both the amplitudal and timely analyses based on the data collected through the reference and monitoring channels.


During the amplitudal analysis the heights of the amplitude of the output from the reference channel are compared to those collected from the monitoring channel. Also, the growth rate of the amplitude in the monitoring channel is analyzed. Finally, the amplitude of the output recorded during various transmural pressures is compared to the maximal amplitude of the output recorded after the running of the occlusion test.


During the timely analysis, plethysmogrphic waveforms collected through the reference and monitoring channels are compared. The output is then normalized and the delay time or phase change is determined.


The technical result in the device is achieved by the three parts, or blocks, of the device. The first of these is a double-channeled sensor block which detects pulse wave signals from peripheral arteries. The second is a pressure block which creates gradually increasing pressure in the blood pressure cuff. The final block is an electronic block which measures the pressure created in the cuff. This pressure corresponds to the maximal amplitude of the PG signal. Along with measuring pressure in the blood pressure cuff, the electronic block also operates the pressure block, which creates pressure in the cuff equal to an assigned percentage of the increase in maximal amplitude. The sensor block is connected to the electronic block, which is in turn hooked up through an outlet to the pressure block.


The technical result is amplified because the pressure block is able to create pressure which is increased gradually by increments of 5 mmHg and time increments of five to ten seconds, in the cuff.


The sensor block in each channel includes an infrared diode and a photoreceptor. Both of these devices are situated so that they are able to read the light signal passing through the observed field.


The infrared diode and the light receptor are also able to sense and record the diffused light signal reflected off the observed field.


The sensor block also includes impedancemetric electrodes, or Hall sensors, or an elastic tube filled with electro-conductive material.


The light receptor is connected to a filter which filters pulse wave component out of the general signal.


The device also includes orthogonally-placed polarized filters which protect the photoreceptor from extraneous exposure to light.


The sensor block finally includes a means for maintaining a set temperature of the observed region of the body.


The device has either a liquid-crystal screen for displaying the results of endothelial tissue assessment, or an interface system connected to the electronic block for transferring the collected data to a computer.





BRIEF DESCRIPTION OF THE DRAWINGS

The essence of the invention and its ability to provide certain results will be easier understood through an example of usage. In this example there will be references made to the drawings below.



FIG. 1 illustrates the dynamic between measurements of total blood flow and the diameter of the shoulder artery during the occlusion test.



FIG. 2 shows a diagram of the formation of a PPG waveform.



FIG. 3 shows a PPG curve while



FIG. 4 shows a family of such waveforms recorded at various magnitudes of transmural pressure in patients of the control group.


Finally, FIG. 5 illustrates the effect of increased hydrostatic pressure on the amplitude of the PPG signal, and



FIG. 6 shows the major block diagram of the device.





DETAILED DESCRIPTION OF THE INVENTION

The apparatus (FIG. 6) is used for assessing the function of endothelial tissue. The device includes a double-channeled sensor block (for simplicity the double channel is shown as single in the figures). Each of the channels has an infrared light diode (2) which is connected to the output of the control (9). It also includes a photoreceptor connected to the input of the electric voltage converter (4). The sensor block records pulse waveforms from peripheral arteries. The pressure block includes a compressor (11), which creates pressure in the cuff (1). This compressor is controlled by the control (9). The pressure block also has a pressure sensor (12) for recording the patient's blood pressure. This pressure sensor (12) is attached to the output of the control (9). Apart from this, the pressure block can be used as a means for applying mechanical pressure on a particular section of an extremity. The electronic block has a programmable control (9), programmed for operating the compressor (11) and turning on the light diode (2), as well as for processing data coming in from the light receptor chain. The input to the control (9) is connected to the output of the pressure sensor (12), which in turn is connected to the converter (4) of the digital analog converter (8) through a sequence of amplifier (5), filter (6), and scalar amplifier (7). On top of that, the control (9) is connected through a set of input-output linkages to a USB interface for connecting to an external computer (not shown). The photoreceptor (3) signal is converted as it moves through a chain of mechanisms which include the converter (4), amplifiers (5 and 7), and filter (6) which can filter the pulse signal out from the overall noise. The device also includes orthogonally-stationed polarized filters (not shown) for filtering out extraneous light which could overexpose the photoreceptor (3). Finally, the device has, in its sensor block, a means of maintaining an assigned temperature of the observed region of the body, as well as a liquid crystal screen connected to the control (9) which displays the results of endothelial function assessment. The cuff (1) is placed over the sensors (2 and 3). In the case where mechanical effort is needed, a drive (for example, one that turns on the panel which acts on the sensors) that is connected to the means of creating a mechanical pressure is placed over the two sensors instead of the cuff.


The electronic block defines the pressure in the cuff (1) which corresponds to the maximal amplitude of the PG signal. This block also controls the pressure block which generates pressure in the cuff (1) equal to a predetermined percentage (50%) of the maximal growth of the pressure magnitude. The sensor block can be created with two different variations. The first variation has the infrared light diode (2) and the photoreceptor (3) stationed on opposite sides of the observed region of the extremity in order to be able to record light signals passing through the observed field. The second variation has the infrared diode (2) and the photoreceptor (3) stationed on the same side of the observed vessel.


Also, the sensor block can be made with impedancemetric electrodes, Hall sensors, or an elastic tube filled with electro-conductive material.


The assessment of endothelial function is founded on the PG output readings obtained by the sensor block which is set up on the upper extremity of the observed patient. The signal coming from the cuff is electrically converted as the pressure increases linearly in the cuff (1) until maximal amplitude of the signal is reached. After this the magnitude of the pressure in the cuff or the locally-applied pressure is fixed and the occlusion test is run. During this procedure the sensor block is set up on the internal side of the cuff (1) or is placed at the end of the device which applies pressure in the area where the artery protrudes on the surface of the skin. A reverse connection based on the amplitude of the PG output is used for automatically establishing the aforementioned pressure. During this procedure the PG signal is sent from the digital analog converter (8) through control (9) to the compressor (11) located in the pressure block.


The occlusion test is done using the cuff which is in close proximity (shoulder, forearm, wrist) to the observed artery (shoulder, radial, or digital artery) At the same time the signal received from the other extremity, where the occlusion test is not done, is used as a reference.


The method for assessing the state of endothelial activity of the observed patient has two major stages. During the first stage, a set of plethysmographic waveforms is recorded as the cuff (1) generates various pressures (or various pressures are applied to the observed artery). The second stage comprises the occlusion itself. The first stage provides information on the elastic qualities of the arterial channel. This information is then used to decide between applying cuff pressure or external pressure during the occlusion test. The measurements of the amplitude of the PG signal taken during the effects of the applied pressure describe the tone quality of smooth muscle in the artery as well as its elastic components (elastin and collagen). Locally-applied pressure us accompanied by changes in transmural pressure, whose magnitude is determined by the difference between arterial pressure and the externally applied pressure. When transmural pressure is weakened, the muscle tone of smooth muscle tissue lowers as well. This lowering is accompanied by the widening of arterial channels. Conversely, when transmural pressure is raised, the arteries become narrower. In this lies the myogenic regulation of blood flow, aimed at maintaining optimal pressure in the microcirculatory system. This is the reason why during changes in the magistral vessel from 150 mmHg to 50 mmHg, the capillary pressure remains practically unchanged.


Changes in the muscle tone of smooth muscle tissue are expressed not only in the narrowing or dilation of arteries, but also in the increased stiffness or compliance of artery walls. Which the lowering of transmural pressure, the smooth muscle apparatus of blood vessel walls relaxes to a certain extent. This relaxation can be seen on the PPG waveform in the form of an increased signal amplitude. Maximal amplitude is reached when the transmural pressure drops to zero. Schematically this is shown in FIG. 4, where the S-shaped curve reveals that the maximal increase of volume is defined at the point where the transmural pressure is close to zero. When pulse waves are applied evenly to various points on the deformation curve, the maximal plethysmographic signal is observed in the area where transmural pressure is nearing zero. When changing transmural pressure, the amplitude of the waveform can increase by over 100% in patients of the control group. The patients in the control group correspond in age and diastolic blood pressure to the patient group showing symptoms of ischemic disease (FIG. 4). Whereas in the patient group diagnosed with ischemic heart disease, the amplitudal growth does not exceed 10-20%.


This dynamic of the changes in the amplitude of the signal during different transmural pressures can be linked only to particulars of visco-elastic qualities of the arterial channel in healthy individuals as well as in individuals suffering from arteriosclerosis in various locations. The smooth muscle tension of the artery can be considered the predominantly viscous component, while the strands of elastin and collagen clearly serve as the elastic components in the structure of vessel walls. By lowering the smooth muscle tension as the reading of the transmural pressure approaches zero, we lessen the input of the viscous component of smooth muscle to the deformation curve. This detailed technique allows a more thorough analysis of the deformation curve of elastic components of artery vessel walls. Also this technique is more advantageous for recording phenomena of reactive hyperemia which occurs after the occlusion test.


The magnitude of diameter increase in the observed artery is believed to be linked to the functioning of endothelial cells. The increase of the pressure during the occlusion test results in an increase of nitric oxide (NO) production by endothelial cells. This phenomenon is called “flow-induced dilation”. If the normal function of endothelial cells is deteriorated, their ability to produce nitric oxide, along with other vaso-active compounds, is diminished. This in turn blocks the vasodilation of vessels. In this situation a full-fledged reactive hyperemia does not occur. At this time this phenomenon is used to reveal the disruption of normal endothelial function, i.e. to reveal endothelial dysfunction. The flow-induced dilation of the vessel occurs as a result of the following order of events: occlusion, blood flow increase, change in pressure acting on endothelial cells, nitric oxide production (as well as adaptation to the increased blood flow), and finally nitric oxide acting on the smooth muscle.


Maximal blood flow volume is reached 1-2 seconds after the removal of the occlusion. It is important to note that during simultaneous monitoring of both blood flow volume and artery dilation, the blood flow increases first and only then does the diameter of the vessel change (FIG. 1). The maximal blood flow speed is reached quickly (within a few seconds), and the increase in artery diameter follows, reaching its maximum in one minute. After that the vessel returns to its original size within 2-3 minutes. Based on the particular state of the elastic module of artery walls in patients suffering from arterial hypertension, it is possible to make an assumption on the potential involvement of excessively stiff arteries in the expression of the endothelial cell response to the occlusion test. One cannot exclude the possibility that with the endothelial cells producing equal amounts of nitric oxide< the response of smooth muscle cells in the artery will be determined by the initial state of the elastic module in arterial walls. In order to normalize the response of the smooth muscle apparatus in arterial walls, it is desirable to have an identical, or if not identical at least similar, level of artery stiffness in various patients. One way to provide a uniform initial state of arterial walls is to select the magnitude of transmural pressure at which the arteries highest level of compliance is reached.


The assessment of the occlusion test results, in terms of reactive hyperemia, can be done not only in the shoulder artery, but in smaller vessels as well.


In order to measure flow-dependent dilation, the optical method was used. This method is based on the increase in the observed artery. The incoming pulse wave stretches the artery walls, thereby increasing the diameter of the vessel. Since during the PPG the optical sensor records the increase in blood flow, (rather than changes in the vessel diameter), which is equal to the square of the radius, the measurement can be made with a high level of precision. FIG. 2 shows the method for obtaining the PPG signal. The photo diode records the light stream which passes through the observed region of the finger. As the artery widens with each pulse wave, the volume of blood passing through it increases. Since hemoglobin in the blood absorbs significant amounts of infrared radiation, this reaction leads to an increase in optical density. The pulse wave increases the diameter of the blood vessel as it passes through it. This phenomenon is the main component of the increase of blood volume in the observed region.



FIG. 3 shows a PPG curve. There are two peaks on the curve—the first represents the contraction of the heart, the second shows the affect of this contraction on the pulse wave. The given curve was obtained with the optical sensor placed on the last of the phalanges of the finger.


Before taking the initial measurements, the compressor (11), following the signal of the control (9), generates a pressure in the cuff (1). The pressure increases gradually, with each step of 5 mmHg lasting 5-10 seconds. As the pressure increases, the transmural pressure drops, reaching zero when the pressure in the cuff equals that of the observed artery. At each step the PPG signal coming from the photoreceptor (3) is recorded. The signal sent from the converter (4) is increased in the amplifier (5) and filtered in the filter (6) where static having the industrial frequency of 50 Hz, along with its harmonics, is screened out. The most significant signal amplification is created by the scalar (instrumental) amplifier. The amplified voltage is sent to the digital analog amplifier (8) and then through the USB interface (10) into the computer. The control (9) determines the pressure at which the signal reaches maximum amplitude. In order to better distinguish between the signal and background static, the measurements are taken synchronously.


The procedure for assessing endothelial activity can be divided into two parts:


1. The transmural pressure is lowered by external pressure applied to a region of the finger (either by the cuff using air, an elastic band, or a mechanical compression), or by changes in the hydrostatic pressure as the extremity is raised to a particular height. The latter procedure can fully replace the pressure applied from the exterior to the vessel wall. In the simplified version of endothelial state assessment, one can eliminate the complex automated system and simply raise and lower the arm. As this is done, one can measure the average blood pressure based on the maximal amplitude of the plethysmographic signal, locate the linear section of the compliancy curve (50% of the maximal growth), and then carry out the occlusion test. The only shortcoming in this approach is the necessity to raise the arm and especially having to run the occlusion test with the arm still in that upraised position.


As the transmural pressure is lowered, the pulse component of the PPG grows. This growth corresponds to the increase in the compliancy of the observed artery. When the gradually-increasing pressure is applied to the finger, one can see the expression of the auto-regulated reaction, and, accordingly, select the optimal conditions (based on the magnitude of the transmural pressure) for the occlusion test (by choosing the steepest part of the curve describing the compliancy of the artery).


2. The artery is closed off by applying super-systolic pressure (of 30 mmHg) for five minutes. After rapidly decreasing the pressure in the cuff set up on the observed artery, the dynamic of the PPG waveform is recorded (with the amplitudal and timely analyses in mind). The changes in the PG signal are recorded simultaneously along the reference and monitoring channels for at least three minutes. During the amplitudal analysis, the magnitude of the amplitudal signal is compared between the reference and monitoring channels, the rate of amplitudal signal increase in the monitoring channel is analyzed, and the relationship between amplitudal signals is established. Also, the maximal amplitude measured during various transmural pressures is compared to the maximal magnitude of the signal recorded after the occlusion test. During the timely analysis the plethysmographic waveforms measured through the reference and monitoring channels, are compared, the signal is normalized, and finally the time of delay or the phase shift is established.


The amplitude of the PPG signal was maximal when the transmural pressure was at zero (that is, the pressure applied to the vessel externally was equal to the average arterial pressure). The calculation was made as follows: diastolic pressure plus ⅓ of the pulse pressure. This arterial response to the externally applied pressure is not dependent on the state of endothelial tissue. The method of choosing the pressure to be applied externally to the artery allows one to test the dynamic of the PPG waveform at the moment of reactive hyperemia in the most optimal area of the artery's compliancy. Also this method has its own intrinsic diagnostic value: Information concerning the rheological characteristics of the artery can be derived from the measurements of a family of PPG curves that are taken at various transmural pressures. This information helps separate the changes linked to the auto-regulative effect of the smooth muscle apparatus in artery walls when it comes to increasing the artery diameter, from the elastic attributes of the artery itself. The diameter increase in the artery, caused by the increased volume of blood found in the observed region, leads to the growth of the constant component of the curve. The component of the curve which represents the pulse also reflects the increase of blood flow volume into the systole. The amplitude of the PPG is determined by the level of compliancy of the arterial wall as pulse wave pressure passes through it. The open space inside the artery itself does not affect the amplitude of the PPG signal. Despite some observed correlation between the one and the other, a complete correlation between the diameter of the vessel and its level of compliancy during the measuring of the transmural pressure is not observed.


At low transmural pressure the artery wall becomes less stiff than it is at normal physiological levels of arterial blood pressure.


The optimization of the transmural pressure test significantly increases its sensitivity and thus allows the detection of pathologies at the earliest stages of endothelial tissue dysfunction. The high sensitivity of the test will effectively assess the success of pharmacological therapy administered to the patient and directed toward the correction of endothelial function.


When pressure in the cuff was raised to 100 mmHg, the output was also constantly increasing, reaching its amplitudal maximum at 100 mmHg. Further increase in cuff pressure lead to a decrease in the amplitude of the PPG output. If the pressure was lowered to 75 mmHg, the amplitude of the PPG output dropped by 50%. Likewise, pressure in the cuff altered the shape of the PPG waveform (refer to FIG. 3).


The change in the shape of the PPG signal consisted of a delayed yet more rapid and drastic systolic growth. These changes reflect the effect of the cuff on the pressure of the blood passing through the observed vessel. This occurs because the magnitude of pressure cause by the cuff is subtracted from the pulse wave pressure in the vessel.


The raising of the aim above the “point of equal blood pressure” (above the level of the heart) makes the use of externally-applied pressure caused by the cuff unnecessary. When the arm is thus raised above the “point of equal blood pressure” to the point of pointing straight up, the position of the arm increases the amplitude of the PPG output. When the arm is lowered to its initial level the PPG output also decreases to its initial level.


The gravitational force is an important factor affecting the transmural pressure. For instance, the transmural pressure in the digital artery of the raised arm is less than the transmural pressure in that same artery when at the level of the heart. The extent to which the transmural pressure changes depends on the density of the blood, the gravitational force acting on the blood, and the distance that is it from the “point of equal blood pressure”.

Ptrh=Ptrho−pgh


Where Ptrh stands for the transmural pressure in the digital artery of the raised hand, Ptrho—the transmural pressure in the digital artery at the level of the heart, p—the density of blood (1.03 g/cm), g—gravitational force (980 cm/sec.), h—distance from the point of equal blood pressure to the digital artery in the upraised arm (90 cm.). With the given distance from the “point of equal blood pressure” the blood pressure of the person standing with the upraised arm is 66 mmHg lower than the average blood pressure in the digital artery, measured at the level of the heart.


In this manner the transmural pressure can be lowered either by increasing the pressure from exterior or by lowering the pressure in the vessel itself. It is relatively simple to lower the pressure in the digital artery: one has to raise the hand above the level of the heart. By gradually raising the arm we lower the transmural pressure in the digital artery. At the same time the amplitude of the PPG output increases significantly. The average pressure in the upraised arm can drop down to 30 mmHg, whereas when the hand is on the level of the heart, the pressure reads at 90 mmHg. Transmural pressure in the region of the knee can be four times as large as the transmural pressure in the arteries of the raised arm. The effect of the hydrostatic pressure on the magnitude of the transmural pressure can be used when assessing the visco-elastic qualities of the artery wall.


The aforementioned inventions have the following advantages:


1. The pressure for the occlusion test is determined individually for each patient.


2. Information about the visco-elastic attributes of the arterial channel is provided (depending on the amplitude of the PG output derived from blood pressure increase).


3. Provide a clearer relationship between output and noise/static.


4. The occlusion test is done in a more a more optimal region of the compliancy of the vessel.


5. The inventions provide information about the rheological characteristics of the artery by taking and recording sets of PPG waveforms during various transmural pressures.


6. The inventions increase the sensitivity of the test, thereby increasing the reliability of endothelial tissue function assessment.


7. Allow detection of a pathology at the earliest stages of disrupted endothelial function.


8. Allow to reliably assess the effectiveness of prescribed pharmaceutical therapies.

Claims
  • 1. A method for noninvasive assessment of endothelial function in a patient, which method comprises: a. lowering a transmural pressure in an artery in an extremity by means of a pressure generating cuff;b. measuring, via a monitoring channel, an amplitude of a plethysmographic signal at various transmural pressures generated in step (a);c. determining a pressure in the pressure generating cuff at which the amplitude of the plethysmographic signal is maximal;d. lowering the pressure in the pressure generating cuff to 50% of the pressure at which said maximal amplitude occurs;e. when the pressure in the pressure generating cuff is 50% of the pressure at which said maximal amplitude occurs, running an occlusion test; wherein running an occlusion test comprises generating a pressure in the pressure generating cuff on an observed region of the extremity which exceeds a measured systolic pressure by at least 50 mmHg for at least 5 minutes;f. lowering the pressure in the pressure generating cuff to zero;g. measuring an amplitude of the plethysmographic signal for at least 3 minutes and simultaneously measuring, via a reference channel, an amplitude of a plethysmographic signal detected from an artery in a second extremity where the occlusion test has not been performed;h. using amplitudal and timely analyses to compare data collected through the reference and monitoring channels; andi. providing an assessment of the patient's endothelial function based on the amplitudal and timely analyses.
  • 2. The method according to claim 1, wherein pressure applied to the extremity is increased gradually, with each step being 5 mmHg and lasting 5-10 seconds, at the same time recording the amplitude of the plethysmographic output.
  • 3. The method according to claim 1, wherein (i) during the amplitudal analysis data from the reference channel are compared to those collected from the monitoring channel; (ii) a rate of the increase of the amplitude in the monitoring channel is analyzed; (iii) a relationship of an amplitude of a maximum plethysmographic signal recorded during various transmural pressures is compared to a maximal amplitude of a plethysmographic signal recorded after the running of the occlusion test; and/or (iv) during the temporal analysis, plethysmographic waveforms collected through the reference and monitoring channels are compared, the plethysmographic waveforms are then normalized and a time delay or phase change is determined.
  • 4. An apparatus for noninvasive assessment of endothelial function comprising a double-channeled sensor unit, capable of detecting pulse wave signals from peripheral arteries, a pneumatic unit capable of creating gradually increasing pressure in a pressure generating cuff, a pressure sensor configured to detect a blood pressure of a patient; and an electronic block configured to perform at least the following steps: a. lowering a transmural pressure in an artery in an extremity by means of a pressure generating cuff;b. measuring, via a monitoring channel, an amplitude of a plethysmographic signal at various transmural pressures generated in step (a);c. determining a pressure in the pressure generating cuff at which the amplitude of the plethysmographic signal is maximal;d. lowering the pressure in the pressure generating cuff to 50% of the pressure at which said maximal amplitude occurs;e. when the pressure in the pressure generating cuff is 50% of the pressure at which said maximal amplitude occurs, running an occlusion test wherein running an occlusion test comprises generating a pressure in the pressure generating cuff on an observed region of the extremity which exceeds a measured systolic pressure by at least 50 mmHg for at least 5 minutes;f. lowering the pressure in the pressure generating cuff to zero;g. measuring an amplitude of the plethysmographic signal for at least 3 minutes and simultaneously measuring, via a reference channel, an amplitude of a plethysmographic signal detected from an artery in a second extremity where the occlusion test has not been performed; andh. using amplitudal and timely analyses to compare data collected through the reference and monitoring channels;
  • 5. The apparatus according to claim 4, wherein the pneumatic unit is capable of generating pressure in the pressure generating cuff which is increased gradually by increments of 5 mmHg with time increments of five to ten seconds.
  • 6. The apparatus according to claim 4, wherein each channel of the double-channeled sensor unit comprises an infrared diode and a photoreceptor, both configured to record a light signal passing through an observed field.
  • 7. The apparatus according to claim 4, wherein each of the channels of the double-channeled sensor unit comprises an infrared light diode and a photoreceptor, both configured to record a diffused light signal reflected off an observed field.
  • 8. The apparatus according to claim 4, wherein (i) the double-channeled sensor unit comprises impedancemetric electrodes, or Hall sensors, or an elastic tube filled with electro-conductive material; or (ii) it additionally comprises orthogonally-placed polarized filters protecting the photoreceptor from extraneous exposure to light.
  • 9. The apparatus according to claim 6, wherein the photoreceptor is connected to a filter configured to filter pulse wave components out of a general signal.
  • 10. The apparatus according to claim 4, further comprising a liquid-crystal screen for displaying results of endothelial tissue assessment, and/or an interface system connected to the electronic block for transferring collected data to a computer.
  • 11. The apparatus according to claim 4, wherein lowering the pressure in the pressure generating cuff to 50% of the pressure at which said maximal amplitude occurs comprises providing optimal arterial compliance.
Priority Claims (1)
Number Date Country Kind
2006105107 Feb 2006 RU national
PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/RU2006/000158 4/3/2006 WO 00 8/10/2010
Publishing Document Publishing Date Country Kind
WO2007/097654 8/30/2007 WO A
US Referenced Citations (231)
Number Name Date Kind
3807389 Miller et al. Apr 1974 A
3903872 Link Sep 1975 A
3980075 Heule Sep 1976 A
4009709 Link et al. Mar 1977 A
4074711 Link et al. Feb 1978 A
4163447 Orr Aug 1979 A
4195643 Pratt, Jr. Apr 1980 A
4406289 Wesseling et al. Sep 1983 A
4432374 Osanai Feb 1984 A
4510940 Wesseling Apr 1985 A
4539997 Wesseling et al. Sep 1985 A
4562843 Djordjevich et al. Jan 1986 A
4566463 Taniguchi et al. Jan 1986 A
4646754 Seale Mar 1987 A
4669485 Russell Jun 1987 A
4677983 Yamaguchi et al. Jul 1987 A
4718426 Russell Jan 1988 A
4718427 Russell Jan 1988 A
4718428 Russell Jan 1988 A
4771792 Seale Sep 1988 A
4798211 Goor et al. Jan 1989 A
4821735 Goor et al. Apr 1989 A
4846189 Sun Jul 1989 A
4850371 Broadhurst et al. Jul 1989 A
4880013 Chio Nov 1989 A
4966141 Bacaner et al. Oct 1990 A
4979110 Albrecht et al. Dec 1990 A
4986277 Sackner Jan 1991 A
4993422 Hon et al. Feb 1991 A
5025792 Hon et al. Jun 1991 A
5040540 Sackner Aug 1991 A
5043576 Broadhurst et al. Aug 1991 A
5048533 Muz Sep 1991 A
5054494 Lazzaro et al. Oct 1991 A
5099852 Meister et al. Mar 1992 A
5119824 Niwa Jun 1992 A
5127408 Parsons et al. Jul 1992 A
5140990 Jones et al. Aug 1992 A
5152297 Meister et al. Oct 1992 A
5161531 Parsons et al. Nov 1992 A
5162991 Chio Nov 1992 A
5241963 Shankar Sep 1993 A
5241964 McQuilkin Sep 1993 A
5269310 Jones et al. Dec 1993 A
5271399 Listerud et al. Dec 1993 A
5297556 Shankar Mar 1994 A
5303711 Sciarra Apr 1994 A
5343867 Shankar Sep 1994 A
5379774 Nishimura et al. Jan 1995 A
5423322 Clark et al. Jun 1995 A
5447163 Apple Sep 1995 A
5485838 Ukawa et al. Jan 1996 A
5511546 Hon Apr 1996 A
5533511 Kaspari et al. Jul 1996 A
5685989 Krivitski et al. Nov 1997 A
5758652 Nikolic Jun 1998 A
5810734 Caro et al. Sep 1998 A
5830131 Caro et al. Nov 1998 A
5833602 Osemwota Nov 1998 A
5876347 Chesney et al. Mar 1999 A
5906581 Tsuda May 1999 A
5935066 Harris Aug 1999 A
5961467 Shimazu et al. Oct 1999 A
5980464 Tsuda Nov 1999 A
6010457 O'Rourke Jan 2000 A
6015393 Hovland et al. Jan 2000 A
6027452 Flaherty et al. Feb 2000 A
6045509 Caro et al. Apr 2000 A
6048318 Chesney et al. Apr 2000 A
6088607 Diab et al. Jul 2000 A
6120459 Nitzan Sep 2000 A
6152881 Raines et al. Nov 2000 A
6162181 Hynson et al. Dec 2000 A
6171242 Amano et al. Jan 2001 B1
6210591 Krivitski Apr 2001 B1
6241680 Miwa Jun 2001 B1
6290651 Chesney et al. Sep 2001 B1
6309359 Whitt et al. Oct 2001 B1
6319205 Goor et al. Nov 2001 B1
6322515 Goor Nov 2001 B1
6331159 Amano et al. Dec 2001 B1
6331161 Chesney et al. Dec 2001 B1
6338719 Drzewiecki et al. Jan 2002 B1
6440080 Booth et al. Aug 2002 B1
6445945 Arsenault Sep 2002 B1
6461305 Schnall Oct 2002 B1
6482163 Oka et al. Nov 2002 B2
6488633 Schnall Dec 2002 B1
6488663 Steg Dec 2002 B1
6491647 Bridger et al. Dec 2002 B1
6517495 Hersh Feb 2003 B1
6554774 Miele Apr 2003 B1
6585659 Chesney et al. Jul 2003 B1
6592528 Amano Jul 2003 B2
6616613 Goodman Sep 2003 B1
6623431 Sakuma et al. Sep 2003 B1
6623434 Chesney et al. Sep 2003 B2
6626840 Drzewiecki et al. Sep 2003 B2
6662130 Peel, III et al. Sep 2003 B1
6629343 Chesney et al. Oct 2003 B1
6632181 Flaherty et al. Oct 2003 B2
6654628 Silber et al. Nov 2003 B1
6719704 Narimatsu et al. Apr 2004 B2
6733461 Bratteli May 2004 B2
6746407 Steuer et al. Jun 2004 B2
6749567 Davis et al. Jun 2004 B2
6757554 Rubinstein et al. Jun 2004 B2
6804543 Miller et al. Oct 2004 B2
6868739 Krivitski et al. Mar 2005 B1
6884221 Narimatsu et al. Apr 2005 B2
6896660 Jelliffe et al. May 2005 B2
6905470 Lee et al. Jun 2005 B2
6908436 Chowienczyk Jun 2005 B2
6915154 Docherty et al. Jul 2005 B1
6916289 Schnall Jul 2005 B2
6937882 Steuer et al. Aug 2005 B2
6939304 Schnall et al. Sep 2005 B2
6939305 Flaherty et al. Sep 2005 B2
6976966 Narimatsu Dec 2005 B2
6987993 Steuer et al. Jan 2006 B2
6994675 Sharrock Feb 2006 B2
7022084 Ogura Apr 2006 B2
7024234 Margulies et al. Apr 2006 B2
7041060 Flaherty et al. May 2006 B2
7048691 Miele et al. May 2006 B2
7056291 Yokozeki et al. Jun 2006 B2
7070569 Heinonen et al. Jul 2006 B2
7074183 Castellanos Jul 2006 B2
7077809 Wu et al. Jul 2006 B2
7121150 Krivitski et al. Oct 2006 B2
7131949 Hayano et al. Nov 2006 B2
7204798 Zdeblick et al. Apr 2007 B2
7214192 Poliac et al. May 2007 B2
7244225 Loeb et al. Jul 2007 B2
7250031 Hayano et al. Jul 2007 B2
7264594 Shimazu et al. Sep 2007 B2
7291112 Martin et al. Nov 2007 B2
7291113 Satoh et al. Nov 2007 B2
7297280 Krivitski et al. Nov 2007 B2
7318804 Weitzel et al. Jan 2008 B2
7374541 Amitzur et al. May 2008 B2
7621877 Schnall Nov 2009 B2
7806831 Lavie et al. Oct 2010 B2
20010025151 Kimball et al. Sep 2001 A1
20020013533 Oka et al. Jan 2002 A1
20020062086 Miele et al. May 2002 A1
20020065471 Amano et al. May 2002 A1
20020072681 Schnali Jun 2002 A1
20020111554 Drzewiecki et al. Aug 2002 A1
20020183599 Castellanos Dec 2002 A1
20030004423 Lavie et al. Jan 2003 A1
20030032885 Rubinstein et al. Feb 2003 A1
20030036685 Goodman Feb 2003 A1
20030040675 Sharrock Feb 2003 A1
20030060690 Jelliffe et al. Mar 2003 A1
20030065270 Raines et al. Apr 2003 A1
20030069507 Nishibayashi Apr 2003 A1
20030191395 Bowman et al. Oct 2003 A1
20030212336 Lee et al. Nov 2003 A1
20030216652 Narimatsu et al. Nov 2003 A1
20030229288 Chowienczyk et al. Dec 2003 A1
20030236464 Narimatsu et al. Dec 2003 A1
20040064057 Siegel Apr 2004 A1
20040092832 Schnall et al. May 2004 A1
20040116787 Schnall Jun 2004 A1
20040127800 Kimball et al. Jul 2004 A1
20040167413 Bratteli Aug 2004 A1
20040215085 Schnall Oct 2004 A1
20040215093 Rubenstein et al. Oct 2004 A1
20040230125 Amano et al. Nov 2004 A1
20040254483 Zdeblick et al. Dec 2004 A1
20040254485 Wu et al. Dec 2004 A1
20040267141 Amano et al. Dec 2004 A1
20050004476 Payvar et al. Jan 2005 A1
20050010928 Arsenault Jan 2005 A1
20050020891 Rubinstein et al. Jan 2005 A1
20050038346 Miele Feb 2005 A1
20050043608 Haj-Yousef Feb 2005 A1
20050070805 Dafni Mar 2005 A1
20050075531 Loeb et al. Apr 2005 A1
20050085712 Rapoport Apr 2005 A1
20050107710 Nakayama May 2005 A1
20050113652 Stark et al. May 2005 A1
20050143633 Jelliffe et al. Jun 2005 A1
20050171443 Gorenberg et al. Aug 2005 A1
20050182434 Docherty et al. Aug 2005 A1
20050228303 Hayano et al. Oct 2005 A1
20050256412 Shimazu Nov 2005 A1
20050267381 Benditt et al. Dec 2005 A1
20060009688 Lamego Jan 2006 A1
20060009700 Brumfield et al. Jan 2006 A1
20060015032 Gordon Jan 2006 A1
20060052713 Poliac et al. Mar 2006 A1
20060052714 Poliac et al. Mar 2006 A1
20060064024 Schnall Mar 2006 A1
20060079791 Letremy et al. Apr 2006 A1
20060104824 Schnall May 2006 A1
20060122489 Kato et al. Jun 2006 A1
20060149152 Amitzur et al. Jul 2006 A1
20060178585 Sharrock Aug 2006 A1
20060206030 Flaherty et al. Sep 2006 A1
20060206032 Miele et al. Sep 2006 A1
20060217614 Takala et al. Sep 2006 A1
20060217615 Huiku et al. Sep 2006 A1
20060229488 Ayre et al. Oct 2006 A1
20060229506 Castellanos Oct 2006 A1
20060229519 Fujiwara et al. Oct 2006 A1
20060241459 Tai Oct 2006 A1
20060247538 Davis Nov 2006 A1
20060258946 Hayano et al. Nov 2006 A1
20060264755 Maltz et al. Nov 2006 A1
20060287600 McEowen Dec 2006 A1
20070021673 Arbel et al. Jan 2007 A1
20070021683 Benditt et al. Jan 2007 A1
20070055163 Asada et al. Mar 2007 A1
20070078351 Fujita et al. Apr 2007 A1
20070106162 Illyes et al. May 2007 A1
20070118045 Naghavi et al. May 2007 A1
20070161914 Zdeblick et al. Jul 2007 A1
20070173727 Naghavi et al. Jul 2007 A1
20070225606 Naghavi et al. Sep 2007 A1
20070270720 Fry Nov 2007 A1
20080004511 Rubenstein et al. Jan 2008 A1
20080013777 Park Jan 2008 A1
20080015434 Rubenstein et al. Jan 2008 A1
20080027298 Blanco et al. Jan 2008 A1
20080027330 Naghavi et al. Jan 2008 A1
20080033307 Baudoin et al. Feb 2008 A1
20080039731 McCombie et al. Feb 2008 A1
20080077024 Schnall Mar 2008 A1
20080139949 Caldarone et al. Jun 2008 A1
Foreign Referenced Citations (93)
Number Date Country
102004016376 Oct 2005 DE
0197302 Oct 1986 EP
0244264 Nov 1987 EP
0262778 Apr 1988 EP
0347101 Dec 1989 EP
0443267 Aug 1991 EP
0694283 Jan 1996 EP
0716829 Jun 1996 EP
0818175 Jan 1998 EP
0997102 May 2000 EP
1175864 Jan 2002 EP
1360929 Nov 2003 EP
1362549 Nov 2003 EP
1374760 Jan 2004 EP
1584289 Oct 2005 EP
1618840 Jan 2006 EP
1704818 Sep 2006 EP
1743572 Jan 2007 EP
1769748 Apr 2007 EP
1849408 Oct 2007 EP
1852061 Nov 2007 EP
1852063 Nov 2007 EP
120109 Dec 2002 IL
120881 Dec 2002 IL
151437 Sep 2007 IL
154833 Sep 2007 IL
5305061 Nov 1993 JP
2938237 Jun 1996 JP
9173307 Jul 1997 JP
2004129979 Apr 2004 JP
2006102252 Apr 2006 JP
2006115979 May 2006 JP
2006181261 Jul 2006 JP
2220653 Jan 2004 RU
2265391 Jul 2005 RU
2004102316 Jul 2005 RU
2302196 Jul 2007 RU
8604801 Aug 1986 WO
8909017 Oct 1989 WO
9001895 Mar 1990 WO
9002512 Mar 1992 WO
9207508 May 1992 WO
9222239 Dec 1992 WO
9305704 Apr 1993 WO
9518564 Jul 1995 WO
9709927 Mar 1997 WO
9712545 Apr 1997 WO
9714356 Apr 1997 WO
9749328 Dec 1997 WO
9804182 Feb 1998 WO
9842255 Oct 1998 WO
9934724 Jul 1999 WO
9939634 Aug 1999 WO
9963884 Dec 1999 WO
0017615 Mar 2000 WO
0032103 Jun 2000 WO
0057776 Oct 2000 WO
0059372 Oct 2000 WO
0074551 Dec 2000 WO
0074563 Dec 2000 WO
0122870 Apr 2001 WO
0164101 Sep 2001 WO
0170303 Sep 2001 WO
0195798 Dec 2001 WO
2002000107 Jan 2002 WO
2002005726 Jan 2002 WO
2002034105 May 2002 WO
WO 0234105 May 2002 WO
02085204 Oct 2002 WO
2002080752 Oct 2002 WO
2002089668 Nov 2002 WO
2002094085 Nov 2002 WO
2002099600 Dec 2002 WO
2003051193 Jun 2003 WO
2003086169 Oct 2003 WO
WO 2003086169 Oct 2003 WO
2004006748 Jan 2004 WO
2004021878 Mar 2004 WO
2004041079 May 2004 WO
2004052196 Jun 2004 WO
2004066817 Aug 2004 WO
2005006975 Jan 2005 WO
2005028029 Mar 2005 WO
2005030038 Apr 2005 WO
2005092178 Oct 2005 WO
2005110051 Nov 2005 WO
2006024871 Mar 2006 WO
2006034542 Jun 2006 WO
2006102511 Sep 2006 WO
2007024777 Mar 2007 WO
2009144598 Dec 2009 WO
2009144721 Dec 2009 WO
2010089745 Aug 2010 WO
Non-Patent Literature Citations (5)
Entry
International Search Report and Written Opinion dated Jul. 6, 2010 regarding PCT/US2010/033907 with a filing date on May 6, 2010.
Tsui, et al., Arterial pulse waveform analysis by the probability distribution of amplitude, 2007, vol. 28, No. 8, Physiological Measurement—attached as reference to International Search Report and Written Opinion dated Jul. 6, 2010 regarding PCT/US2010/033907.
Semkin, ND, Diagnosis of vascular endothelial function in patients with cardiovascular disease Methodological guidelines, 2004, 17 pp., Samara State Aerospace University.
Supplementary Search Report of EP Application No. 06784054.6, dated Aug. 8, 2009, 6 pages total.
International Preliminary Report on Patentability of PCT Application No. PCT/RU2006/000158, dated Dec. 10, 2008, 8 pages total.
Related Publications (1)
Number Date Country
20100298717 A1 Nov 2010 US